Evidence map›Paper›PMID 32621746›Full record

ArticleThe Journal of infectious diseases2021

Implication of a High Risk for Type 2 Vaccine-Derived Poliovirus Emergence and Transmission After the Switch From Trivalent to Bivalent Oral Poliovirus Vaccine.

Dongmei Yan, Dongyan Wang, Yong Zhang, Xiaolei Li, Haishu Tang, Jing Guan, Yang Song, Shuangli Zhu, Wenbo Xu

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Dongmei YanWorld Health Organization Western Pacific Regional Office Regional Reference Poliomyelitis Laboratory and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Dongyan WangWorld Health Organization Western Pacific Regional Office Regional Reference Poliomyelitis Laboratory and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yong ZhangWorld Health Organization Western Pacific Regional Office Regional Reference Poliomyelitis Laboratory and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Xiaolei LiWorld Health Organization Western Pacific Regional Office Regional Reference Poliomyelitis Laboratory and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Haishu TangXinjiang Uyghur Autonomous Region Center for Disease Control and Prevention, Urumqi, China.
Jing GuanXinjiang Uyghur Autonomous Region Center for Disease Control and Prevention, Urumqi, China.
Yang SongWorld Health Organization Western Pacific Regional Office Regional Reference Poliomyelitis Laboratory and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Shuangli ZhuWorld Health Organization Western Pacific Regional Office Regional Reference Poliomyelitis Laboratory and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Wenbo XuWorld Health Organization Western Pacific Regional Office Regional Reference Poliomyelitis Laboratory and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChina implemented the globally synchronized switch from trivalent oral poliovirus vaccine (tOPV) to bivalent OPV (bOPV) and introduced 1 dose of inactivated poliovirus vaccine on 1 May 2016. We assessed the impact of the switch on the immunity level against poliovirus, especially type 2.

methodsChildren born between 2014 and 2017, who were brought to the hospitals in Urumqi city, Xinjiang Province in 2017, were enrolled and blood samples were collected to test for antibody titers against poliovirus. A comparison of seroprevalence between the children born before (preswitch group) and after the switch (postswitch group) was performed to assess the impact of the switch on the immunity level against polio.

resultsA total of 172 subjects were enrolled. The overall seroprevalences were 98.8%, 79.1%, and 98.3% for types 1, 2, and 3, respectively. Seroprevalence for type 2 significantly decreased from 91.6% in the preswitch group to 67.4% in the postswitch group, but no statistically significant change was observed for both types 1 and 3.

conclusionsThe switch from tOPV to bOPV can provide high-level immunity against types 1 and 3 but not against type 2, indicating a high risk of type 2 vaccine-derived poliovirus emergence and transmission.

Indexed as

Child, PreschoolChinaCross-Sectional StudiesFemaleHumansImmunization ScheduleInfantInfant, NewbornMalePoliomyelitisPoliovirusPoliovirus Vaccine, InactivatedPoliovirus Vaccine, OralSeroepidemiologic StudiesPoliovirus Vaccine, InactivatedPoliovirus Vaccine, Oralinactivated poliovirus vaccineoral poliovirus vaccinepoliovirusseroprevalenceswitch

Identifiers

PMID32621746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.